Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet ...Middle East

Dupixent is the first and only biologic that significantly improved skin clearance, and reduced itch and overall disease severity in children as young as 6 months old in a Phase 3 trial Published results reinforce well-established efficacy and safety profile of Dupixent across age groups...

Hence then, the article about positive dupixent dupilumab phase 3 data in children aged 6 months to 5 years with moderate to severe atopic dermatitis published in the lancet was published today ( Friday 16/09/2022 - 01:52 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet )

Also on site :

• Fortnite Ben 10 collaboration: Release date, what to expect & more
• Exclusive: Omni raises $120 million to fix one of AI’s biggest enterprise data problems
• Citizens Bank Customers Targeted in Third-Party Data Breach .. PYMNTS.com